COMP <GO>
BSX vs MRK // EV/EBITDA & P/E VALUATION
Boston Scientific Corporation (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: BSX 4
— MRK 11
▲ EV/EBITDA & P/E VALUATION LEADER: MRK
LAST: $41.98 (-1.66%) • MKT CAP: $61.87B
valuation
15.8x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BSX VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BSX | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.00% | 74.80% | -5.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.20% | 20.70% | -11.50 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 15.8x | 15.3x | +0.50 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 5.91% | 3.42% | +2.49 | BSX | /fcf-yield <GO> |
| Operating Margin | 18.00% | 34.30% | -16.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | 14.00% | 28.10% | -14.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 19.90% | 1.30% | +18.60 | BSX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.77 | 5.19 | -2.42 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | BSX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.60% | +0.30 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.8 | 56.9 | -18.09 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 0.92 | +0.07 | BSX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.5x | 18.4x | +0.10 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $61.87B | $361.02B | -$299.15B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BSX REV | MRK REV | BSX GROSS % | MRK GROSS % | BSX FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $20.07B | $65.01B | 69.0% | 74.8% | $3.66B | $12.36B |
| FY 2024 | $16.75B | $64.17B | 68.6% | 76.3% | $2.65B | $18.10B |
| FY 2023 | $14.24B | $60.12B | 44.0% | 44.0% | $1.86B | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BSX // BETA 0.99
MRK // BETA 0.92